Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — FY2017 Earnings Presentation
12 slides from Thyrocare Technologies's earnings presentation, May 9, 2017
Slide 1: Thyrocare
Thyrocare Think Thyroid. Think Thyrocare. May 11, 2017 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation and Media Release on
Slide 2: FY17 results presentation
FY17 results presentation May 09, 2017 Registered Office : D/37-1, TTC MIDC, Turbhe, Page | 1 Thyrocare Technologies Limited Navi Mumbai ~ 400703. [Stock Code NSE/ BSE - THYROCARE] CIN : U85110MH2000PLC123882
Slide 3: 2017 FY Key Highlights
eee ec5o 2017 FY Key Highlights °° CY - Consolidated revenue & 3068.06 million (PY z 2409.65 million) - Growth of 27% CY - Consolidated EBITDA € 1183.70 million - EBITDA margin 39% CY - Consolidated PAT = 709.65 million — PAT margin 22% CY — Revenue from pathology = 2885.11 million (PY % 2254.11 mil
Slide 4: Financial overview - pathology
Financial overview - pathology Zin million Key Financials - 2017FY 2016FY 2015FY Pathology Revenue * 2,885.11 2,254.11 1,778.42 Cost of material / tests * (896.62) (701.95) (565.07) 2 > ors Cost of personnel (298.50) (247.19) (174.31) Thyt @) C ATe Other expenses * (489.77) (367.02) (303.47) o/ ——_
Slide 5: Financial overview - radiology
Financial overview - radiology Zin million Key Financials - 2017FY 2016FY 2015FY Radiology Revenue * 182.95 155.54 118.83 Cost of material * (31.77) (33.74) ~— (42.81) Cost of personnel ? (37.98) (32.98) (28.64) Other expenses * (87.83) (83.80) (63.68) EBITDA 25.37 5.02 (16.30) EBITDA Margin 13.9% 3
Slide 6: Regional review - pathology
Regional review - pathology Zin million * cloud - through direct sales associates, corporates, instotutions and online Page |5 Thyrocare Technologies Limited [Stock Code NSE/ BSE - THYROCARE]}
Slide 7: Center-wise — PET-CT
Center-wise — PET-CT Zin million New PET-CT centre proposed in 2017 FY 2016 FY the current financial year Revenue Noof Revenue - Raipur, CG (awaiting for license from See scans AERB) New delhi - Nashik, MH (awaiting for site approval 7 from AERB) Navi mumbai 64.85 7078 6651 - Mumbai — Borivali, MH (
Slide 8: Preventive care - AAROGYAM
Preventive care - AAROGYAM Aarogyam es Think Wellness. Think Aarogyam Volumes Aarogyam Revenue - - CY constitutes 52% of pathology revenue (PY 46%) - CY 45% higher as compared to PY B2C component - - in revenue % 626.65 million (24%) [PY = 383.38 million (19%)] Number of samples (in millions) Aarogy
Slide 9: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company's activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 10: Media Release
Thurs care I hy ICQUaLL Think Thyroid, Think Thyrocare Media Release Mumbai, 9th May 2017 RECORD ANNUAL CONSOLIDATED NET PRoFiT OF € 709.65 MILLION, Up 37% REcorp ANNUAL CONSOLIDATED EBIDTA OF € 1183.70 MiLLion, Up 27% ReEcorp ANNUAL CONSOLIDATED Revenue OF & 3068.06 MILLION, Up 27% QuARTERLY CONSOL
Slide 11: Media Release
Thyrocare Think Thyroid. Think Thyrocare Media Release Thyrocare Technologies Limited has widespread business across the country with touch points scattered pan India. During the financial year, the company has generated around 29% of total revenue from West, 26% from South, 21% from North and aroun
Slide 12: Media Release
Think Thyroid. Think Thyrocare Media Release to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the company, its future financial conditi
Thyrocare Technologies — FY2017 Earnings Presentation on 6ix